News

Dennis J. Slamon, MD, discusses the rationale of the phase 3 NATALEE trial and ribociclib for the treatment of patients with HR+/HER2- early breast cancer.

Rohan Garje, MD, discusses the goals of his research in assessing the outcomes of sarcomatoid vs classic urothelial carcinoma of bladder.

Findings from the 5-year follow-up analysis of the phase 3 KEYNOTE-042 study continue to support frontline pembrolizumab as standard of care for PD-L1-positive, locally advanced/metastatic non–small cell lung cancer.

Following promising phase 1 study results, the combination of selinexor and ruxolitinib is being evaluated in a phase 3 trial in patients with myelofibrosis.

According to investigators of the phase 3 HIMALAYA trial, updated findings confirm the role of the STRIDE regimen in the unresectable hepatocellular carcinoma treatment paradigm.

Lisa B. Ercolano, MD, discusses the treatment of sarcomas in an era of molecular medicine.

In an interview, Harry Erba, MD, PhD, compared ziftomenib with other Menin inhibitors and discussed data from the phase 1/2 trial evaluating the menin-KMT2A inhibitor in patients with AML.

Lori Muffly, MD, discusses findings a sub-analysis of a phase 1 study investigating briquilimab with low-dose total body radiation and fludarabine.

In an interview, Emma Searle, MBChB, PhD, MA, MRCP, FRCPath, discussed results from cohort E of the MajesTEC-2 study of teclistamab in relapsed/refractory multiple myeloma.

Treatment with the investigational drug FHD-286 exhibits positive results in patients with metastatic uveal melanoma and will be explored further in acute myeloid leukemia and myelodysplastic syndrome.

A phase 1 study is assessing the safety and tolerability of briquilimab in patients with lower-risk myelodysplastic syndrome.

A fast track designation has been granted by the FDA to quaratusugene ozeplasmid with atezolizumab for the treatment patients with extensive-stage small cell lung cancer.

The phase 2b VIRAGE study will investigate the safety and efficacy of VCN-01 plus standard chemotherapy in patients with first-line pancreatic ductal adenocarcinoma.

Jennifer R. Brown, MD, PhD, highlights the results from the phase 3 ALPINE study evaluating the treatment with zanubrutinib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

E-602 represents the first glyco-immune checkpoint inhibitor and the early safety as well as translational immunology associated with the treatment in patients with advanced cancer is promising, according to Jason Luke, MD, FACP.

Topline results from the EPCORE NHL-1 trial showed promising efficacy findings and no new safety signals with epcoritamab in a cohort of 128 patients with relapsed/refractory follicular lymphoma.

According to the developer of TTI-101, the REVERT-Liver Cancer trial is the second of three phase 2 trials involving the agent.

Durable responses in patients with metastatic pancreatic ductal adenocarcinoma treated with mitazalimab plus chemotherapy have led to discussions with regulatory authorities.

Updates to the NCCN guidelines will help clinicians treat their patients with acute lymphoblastic leukemia, B-cell lymphomas, pediatric acute lymphoblastic leukemia, and pediatric aggressive mature B-cell lymphomas on high-dose methotrexate.

The National Comprehensive Cancer Network has updated its guidelines to include the recently approved T-cell engaging bispecific antibody epcoritamab for B-cell lymphomas.

In an interview with Targeted Oncology, Benjamin Besse, MD, PhD, discussed recently reported results from the phase 1/1b CHRYSALIS-2 of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.

Promise has been shown with serplulimab plus HLX04 for the treatment of advanced hepatocellular carcinoma, according to phase 2 international research.

Although drug shortages are not new, the number of drugs involved is increasing and resolutions seem to take longer, and oncology care is often affected by these shortages.

Among patients with unresectable or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma, envafolimab generated positive efficacy data with a well-tolerated safety profile.

The speed at which immunotherapy is adopted by oncology practices depends on their size, location, and affiliation, according to an analysis.

In an interview with Targeted Oncology, Jorge Cortes, MD, highlights the use of olutasidenib in patients with relapsed/refractory acute myeloid leukemia.

Very high tumor burden is a potential biomarker that may predict response to anti–PD-L1 therapy in patients of Asian descent across cancer types.

Hatem Soliman, MD, discusses fam-trastuzumab deruxtecan-nxki and its importance for patients with HER2-positive breast cancer.

In an interview with Targeted Oncology, Ajay K. Nooka, MD, MPH, FACP, discussed data from a pooled analysis of studies from the MagnetisMM program evaluating erlanatamab in relapsed/refractory multiple myeloma.

Karim Fizazi, MD, discusses the toxicities seen with the combination of talazoparib plus enzalutamide.